CAMBRIDGE Mass., March 16, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (NASDAQ: RUBY) (“Rubius”), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells
to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announces the pricing of an upsized underwritten public offering of 6,896,552 shares of its common stock at